person · Reporting owner

Oxtoby Andrew

Disclosed activity across 3 companies

Tapewire entity: 56840
SEC CIK: 0001765473

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Kalaris Therapeutics, Inc.KLRS · Entity 6805	Director · See Remarks	March 19, 2026	March 20, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Kalaris Therapeutics, Inc.

Report date March 19, 2026 · Filed March 20, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.81 · Expires 2036-03-18	Direct	222,000	Reported balance After 2026-03-19 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-03-19 · Grant · Acquired 222,000 · Balance 222,000 F1: The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

Filing footnotes · ownership attribution and instrument terms

F1: The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Aimmune Therapeutics, Inc.

Report date October 10, 2020 · Filed October 14, 2020

Section 16 reporting ended · disclosed 2020-10-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, $0.0001 par valueSEC Table I · non-derivative	Direct	Reported balance After 2020-10-10 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2020-10-10 · Other · Disposed 6,345 · Balance 0
Common Stock, $0.0001 par valueSEC Table I · non-derivative	Direct	Reported balance After 2020-10-13 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2020-10-13 · Disposition to issuer · Disposed 20,250 · Balance 0 F1: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price"). F2: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.94	Direct	Reported balance After 2020-10-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-10-13 · Disposition to issuer · Disposed 150,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.81	Direct	Reported balance After 2020-10-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-10-13 · Disposition to issuer · Disposed 67,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price").

F2: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU.

F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

CHINOOK THERAPEUTICS, INC.

Report date August 11, 2023 · Filed August 11, 2023

Section 16 reporting ended · disclosed 2023-08-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.82 · Expires 2033-02-27	Direct	0	Reported balance After 2023-08-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-08-11 · Disposition to issuer · Disposed 160,000 · Balance 0 F1: This stock option award, which provided for 25% of the award to vest on February 28, 2024 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger (defined in the Remarks below), and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one contingent value right ("CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the contingent value rights agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2023-08-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-08-11 · Disposition to issuer · Disposed 40,000 · Balance 0 F2: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F3: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 28, 2024. Pursuant to the Merger Agreement (defined in the Remarks below), at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

Filing footnotes · ownership attribution and instrument terms

F1: This stock option award, which provided for 25% of the award to vest on February 28, 2024 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger (defined in the Remarks below), and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one contingent value right ("CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the contingent value rights agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.

F2: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement.

F3: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 28, 2024. Pursuant to the Merger Agreement (defined in the Remarks below), at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 19, 2026 Filed Mar 20, 2026 20:05 UTC	Kalaris Therapeutics, Inc. KLRS · Entity 6805	GrantStock Option (Right to Buy) · Derivative	222,000	$0.00 Strike: $6.81	$0.00	Disclosure SEC source: 0001193125-26-117618 · ownership.xml · derivative · entry 1 Oxtoby Andrew · CIK 0001765473 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,000 Underlying: Common Stock · 222,000 shares Expires 2036-03-18 F1 · derivative.exercise_date: The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service. Read SEC document
April 10, 2025 Filed Apr 11, 2025 20:55 UTC	Kalaris Therapeutics, Inc. KLRS · Entity 6805	GrantStock Option (Right to Buy) · Derivative	287,000	$0.00 Strike: $7.31	$0.00	Disclosure SEC source: 0000950170-25-053347 · ownership.xml · derivative · entry 1 Oxtoby Andrew · CIK 0001765473 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 287,000 Underlying: Common Stock · 287,000 shares Expires 2035-04-09 F1 · derivative.exercise_date: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 18, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service. Read SEC document
March 18, 2025 Filed Mar 18, 2025 21:41 UTC	Kalaris Therapeutics, Inc. KLRS · Entity 6805	GrantStock Option (right to buy) · Derivative	476,611	Not disclosed Strike: $0.85	Not disclosed	Disclosure SEC source: 0000950170-25-041485 · ownership.xml · derivative · entry 1 Oxtoby Andrew · CIK 0001765473 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 476,611 Underlying: Common Stock · 476,611 shares Expires 2034-05-27 F1 · date: Stock option assumed in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the "Merger Agreement"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation ("KTx"), in exchange for an outstanding option to purchase shares of KTx pursuant to the terms and conditions of the Merger Agreement (such transaction, the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect an exchange ratio equal to 0.2016 per share, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger. F2 · derivative.exercise_date: This option vests over four years beginning on the vesting commencement date of March 4, 2024, with 25% of the shares underlying the option having vested on March 4, 2025, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter. Read SEC document
August 11, 2023 Filed Aug 11, 2023 16:11 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Disposition to issuerRestricted Stock Units · Derivative	40,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-045429 · doc4.xml · derivative · entry 2 Oxtoby Andrew · CIK 0001765473 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires not disclosed F2 · derivative.exercise_price: When granted, each restricted stock unit ("RSU") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement. F3 · price: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 28, 2024. Pursuant to the Merger Agreement (defined in the Remarks below), at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F3 · derivative.exercise_date: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 28, 2024. Pursuant to the Merger Agreement (defined in the Remarks below), at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. F3 · derivative.expiration_date: When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 28, 2024. Pursuant to the Merger Agreement (defined in the Remarks below), at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR. Read SEC document
August 11, 2023 Filed Aug 11, 2023 16:11 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	Disposition to issuerStock Option (Right to Buy) · Derivative	160,000	$18.18 Strike: $21.82	$2,908,800.00	Disclosure SEC source: 0001209191-23-045429 · doc4.xml · derivative · entry 1 Oxtoby Andrew · CIK 0001765473 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 160,000 shares Expires 2033-02-27 F1 · derivative.exercise_date: This stock option award, which provided for 25% of the award to vest on February 28, 2024 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger (defined in the Remarks below), and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one contingent value right ("CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the contingent value rights agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. Read SEC document
February 28, 2023 Filed Mar 2, 2023 17:00 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	GrantRestricted Stock (RSU)(Common Stock) · Derivative	40,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-014787 · doc4.xml · derivative · entry 2 Oxtoby Andrew · CIK 0001765473 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 28, 2024, until fully vested subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 28, 2024, until fully vested subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
February 28, 2023 Filed Mar 2, 2023 17:00 UTC	CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632	GrantStock Option (right to buy) · Derivative	160,000	$0.00 Strike: $21.82	$0.00	Disclosure SEC source: 0001209191-23-014787 · doc4.xml · derivative · entry 1 Oxtoby Andrew · CIK 0001765473 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2033-02-27 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 28, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
October 13, 2020 Filed Oct 14, 2020 16:15 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	Disposition to issuerStock Option (right to buy) · Derivative	67,500	$10.69 Strike: $23.81	$721,575.00	Disclosure SEC source: 0000899243-20-028183 · doc4.xml · derivative · entry 4 Oxtoby Andrew · CIK 0001765473 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 67,500 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. Read SEC document
October 13, 2020 Filed Oct 14, 2020 16:15 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	Disposition to issuerStock Option (right to buy) · Derivative	150,000	$12.56 Strike: $21.94	$1,884,000.00	Disclosure SEC source: 0000899243-20-028183 · doc4.xml · derivative · entry 3 Oxtoby Andrew · CIK 0001765473 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. Read SEC document
October 13, 2020 Filed Oct 14, 2020 16:15 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	Disposition to issuerCommon Stock, $0.0001 par value	20,250	$34.50	$698,625.00	Disclosure SEC source: 0000899243-20-028183 · doc4.xml · nonDerivative · entry 2 Oxtoby Andrew · CIK 0001765473 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price"). F2 · shares: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU. Read SEC document
October 10, 2020 Filed Oct 14, 2020 16:15 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	OtherCommon Stock, $0.0001 par value	6,345	$34.50	$218,902.50	Disclosure SEC source: 0000899243-20-028183 · doc4.xml · nonDerivative · entry 1 Oxtoby Andrew · CIK 0001765473 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document
September 15, 2020 Filed Sep 16, 2020 17:19 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	Tax withholdingCommon Stock, $0.0001 par value	840	$34.25	$28,770.00	Disclosure SEC source: 0000899243-20-025349 · doc4.xml · nonDerivative · entry 1 Oxtoby Andrew · CIK 0001765473 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,595 F1 · kind: The reported sale was made pursuant to a pre-determined election to sell shares to cover tax withholding obligations in connection with the vesting of a previously reported equity award F2 · balance_after: Includes 11,250 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date F3 · balance_after: Includes 9,000 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from January 19, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
May 10, 2020 Filed May 12, 2020 17:20 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	GrantCommon Stock, $0.0001 par value	2,420	$0.00	$0.00	Disclosure SEC source: 0000899243-20-012853 · doc4.xml · nonDerivative · entry 1 Oxtoby Andrew · CIK 0001765473 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,435 F1 · shares: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest as to 100% of the underlying shares on September 11, 2020 (the "Vesting Date"), subject to the Reporting Person's continued service relationship with the Issuer on the Vesting Date. F1 · balance_after: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest as to 100% of the underlying shares on September 11, 2020 (the "Vesting Date"), subject to the Reporting Person's continued service relationship with the Issuer on the Vesting Date. F2 · balance_after: Includes 11,250 RSUs and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date F3 · balance_after: Includes 9,000 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from January 19, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
March 13, 2020 Filed Mar 17, 2020 16:51 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	PurchaseCommon Stock, $0.0001 par value	3,000	$14.76	$44,265.90	Disclosure SEC source: 0000899243-20-008621 · doc4.xml · nonDerivative · entry 1 Oxtoby Andrew · CIK 0001765473 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,015 F1 · price: Represents the weighted average purchase price for the entire number of shares purchased. The actual purchase prices range from $14.5450 to $14.8500 per share. Information on the exact number of shares purchased at each purchase price can be obtained from the Issuer upon request. F2 · balance_after: Includes 11,250 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date F3 · balance_after: Includes 9,000 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from January 19, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
February 28, 2020 Filed Mar 3, 2020 20:35 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	GrantStock Option (right to buy) · Derivative	67,500	$0.00 Strike: $23.81	$0.00	Disclosure SEC source: 0000899243-20-006850 · doc4.xml · derivative · entry 2 Oxtoby Andrew · CIK 0001765473 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2030-02-28 F3 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
February 28, 2020 Filed Mar 3, 2020 20:35 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	GrantCommon Stock, $0.0001 par value	11,250	$0.00	$0.00	Disclosure SEC source: 0000899243-20-006850 · doc4.xml · nonDerivative · entry 1 Oxtoby Andrew · CIK 0001765473 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,250 F1 · shares: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F1 · balance_after: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F2 · balance_after: Includes 12,000 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from January 19, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
February 28, 2020 Filed Mar 4, 2020 21:53 UTC Amendment	Aimmune Therapeutics, Inc. AIMT · Entity 145931	GrantStock Option (right to buy) · Derivative	67,500	$0.00 Strike: $23.81	$0.00	Disclosure SEC source: 0000899243-20-007111 · doc4a.xml · derivative · entry 2 Oxtoby Andrew · CIK 0001765473 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2030-02-28 F3 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
February 28, 2020 Filed Mar 4, 2020 21:53 UTC Amendment	Aimmune Therapeutics, Inc. AIMT · Entity 145931	GrantCommon Stock, $0.0001 par value	11,250	$0.00	$0.00	Disclosure SEC source: 0000899243-20-007111 · doc4a.xml · nonDerivative · entry 1 Oxtoby Andrew · CIK 0001765473 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,015 F1 · shares: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F1 · balance_after: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. F2 · balance_after: Includes 9,000 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from January 19, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
January 22, 2020 Filed Mar 4, 2020 21:49 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	Tax withholdingCommon Stock, $0.0001 par value	1,235	$33.23	$41,039.05	Disclosure SEC source: 0000899243-20-007110 · doc4.xml · nonDerivative · entry 1 Oxtoby Andrew · CIK 0001765473 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,765 F1 · kind: The reported sale was made pursuant to a pre-determined election to sell shares to cover tax withholding obligations in connection with the vesting of a previously reported equity award. F1 · shares: The reported sale was made pursuant to a pre-determined election to sell shares to cover tax withholding obligations in connection with the vesting of a previously reported equity award. F2 · balance_after: Includes 9,000 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from January 19, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
January 22, 2019 Filed Jan 24, 2019 16:06 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	GrantStock Option (right to buy) · Derivative	150,000	$0.00 Strike: $21.94	$0.00	Disclosure SEC source: 0000899243-19-001869 · doc4.xml · derivative · entry 2 Oxtoby Andrew · CIK 0001765473 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-01-22 F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on January 22, 2020 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document
January 22, 2019 Filed Jan 24, 2019 16:06 UTC	Aimmune Therapeutics, Inc. AIMT · Entity 145931	GrantCommon Stock, $0.0001 par value	12,000	$0.00	$0.00	Disclosure SEC source: 0000899243-19-001869 · doc4.xml · nonDerivative · entry 1 Oxtoby Andrew · CIK 0001765473 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · shares: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from January 22, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.